KIT and acute myeloid leukemia: The prevalence of marker expression in AML blasts [after the exclusion of t(15;17) AML blasts] was 76.5% for CD34, 79.78% for CD117, and 90.12% for HLA-DR, as reported by Webber et al. (2008).